175 research outputs found
Predicting the severity of viral bronchiolitis in children
Acute viral bronchiolitis is one of the common causes of hospitalization and mortality, especially among children in the first year of life who have risk factors (prematurity, congenital heart defects, bronchopulmonary dysplasia, immunosuppression). As factors associated with the severe course of bronchiolitis, along with the traditional ones, single nucleotide polymorphisms of the genes of the immune response molecules can be considered.The aim. Based on the analysis of clinical, laboratory and molecular genetic parameters, to identify prognostic criteria for the severe course of acute viral bronchiolitis in children.Materials and methods. The study included 106 children with acute viral bronchiolitis (severe course β 34, mild course β 72), the etiology of which in 67.9 % was respiratory syncytial virus. Forty-seven anamnestic, clinical, traditional laboratory and molecular genetic parameters were assessed as prognostic criteria. Determination of SNP genes of cytokines IL-4 (C-589T), IL-10 (G-1082A), IL-10 (C-592A), IL-10 (C-819T), TNF-Ξ± (G-308A), IL-17A (G197A), IL-17F (His161Arg), TLR2-753ArgGln, TLR6-Ser249Pro in venous blood was carried out by the polymerase chain reaction method.Results. An additional criterion for the risk of developing a severe course of bronchiolitis can be the mutant genotype (AA) SNP of the IL-10 gene (C-592A), which was detected exclusively in the group of patients with severe bronchiolitis, increasing the risk of developing a severe disease by 16.11 times (OR = 16.11; 95 % CI: 0.81β121.22, p = 0.02) in conjunction with already established modifying factors: the presence of congenital heart disease, bronchopulmonary dysplasia, prematurity, birth weight < 1500 g. Based on a comprehensive assessment of the established risk factors, a method has been developed that allows calculate the likelihood of developing a severe course of acute viral bronchiolitis. Conclusion. The use of the developed prediction method will not only increase the likelihood of developing severe acute viral bronchiolitis in children, but also determine the priority group among children with predictors of severe viral bronchiolitis for priority immunoprophylaxis against RS-virus infection
Financial statements of a company as an information base for decision-making in a transforming economy
In connection with the development of transforming the economy, the need for forecasting and analyzing the consequences of managerial decisions becomes more pressing. To substantiate and evaluate such decisions, a tool for prospective analysis of financial statements of companies is used. In recent years, the content and structure of a company's financial statements have undergone significant changes. With the development of economic relations, the principles of organization and methodology of accounting and reporting are also dynamically changing. The issues of reforming financial statements of a company are constantly discussed at international congresses of accountants and other professional forums.
The purpose of the study is to improve the concept of preparing financial statements of a company as an information base for taking decisions in a transforming economy.
As a result of the research, the economic essence of company's financial statements is substantiated from the point of view of an integrated approach; the importance of financial statements of an organization for effective management is determined; the main financial and non-financial indicators are systematized; it is proposed to introduce a mandatory requirement for disclosure of non-financial indicators in the corporate reporting system; proposals have been elaborated to improve the methods for analyzing financial statements as a tool for managing a company.peer-reviewe
DETECTION OF CRYPTOSPORIDIUM AND CHARACTERIZATION OF THE INTESTINAL MICROFLORA IN CHILDREN WITH ACUTE INTESTINAL INFECTIONS
This paper presents results, which were obtained during investigation of 106 children with acute intestinal infections in order to determine the presence of cryptosporidia and to evaluate their intestinal microbial status. The cryptosporidia's oocysts were found in 31 of children (29,2 %) that were mainly under the 3 age old. At the same time the authors found the dysbacteriosis of the second and. third, degrees in 92,5 % of patients. Six patients (5,7 %) became cryptosporidium negative and improved their intestinal microbial status. The obtained results showed that lactobacterias containing probiotics are effective in treatment of children with acute intestinal infections for normalizing of intestinal biocenosis and. to eradicate cryptosporidia
ΠΠΠΠ‘ΠΠΠΠΠΠΠ ΠΠ«ΠΠΠ Π ΠΠΠ’ΠΠΠΠΠ¬ΠΠΠ ΠΠ ΠΠΠΠΠ’ΠΠ§ΠΠ‘ΠΠΠ Π’ΠΠ ΠΠΠΠ ΠΠ‘Π’Π Π«Π₯ ΠΠΠ¨ΠΠ§ΠΠ«Π₯ ΠΠΠ€ΠΠΠ¦ΠΠ Π£ ΠΠΠ’ΠΠ Π‘ Π€Π£ΠΠΠ¦ΠΠΠΠΠΠ¬ΠΠΠ Π Π₯Π ΠΠΠΠ§ΠΠ‘ΠΠΠ ΠΠΠ’ΠΠΠΠΠΠΠ ΠΠΠΠ£ΠΠΠ§ΠΠ-ΠΠΠ¨ΠΠ§ΠΠΠΠ Π’Π ΠΠΠ’Π
Studied the comparative efficacy of probiotics with different composition of strains in the complex treatment of acute intestinal infection in 89 children with functional disorders and chronic gastrointestinal tract. Conducted a dynamic study of the intestinal microflora bacteriological method and gas-liquid chromatography with the definition of short-chain fatty acid content of the level of carbohydrates in the feces and stool data. Set different dates for stopping diarrhea and features state of the intestinal ecosystem indicators after treatment in patients receiving comprehensive probiotic containing bifidobacteria and enterococcus, or probiotic containing lactobacillus.Β ΠΠ·ΡΡΠ΅Π½Π° ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΎΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΡΡΠ°ΠΌΠΌΠΎΠ²ΡΠΌ ΡΠΎΡΡΠ°Π²ΠΎΠΌ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΡΠΎΠΉ ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ 89 Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΡΠ»ΠΎΡΡ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π³Π°Π·ΠΎΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΠΎΠΉ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΡΠΎΡΠΊΠΎΡΠ΅ΠΏΠΎΡΠ΅ΡΠ½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΡΠ³Π»Π΅Π²ΠΎΠ΄ΠΎΠ² Π² ΡΠ΅ΠΊΠ°Π»ΠΈΡΡ
ΠΈ ΠΊΠΎΠΏΡΠΎΡΠΈΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΡΠΎΠΊΠΈ Π»ΠΈΠΊΠ²ΠΈΠ΄Π°ΡΠΈΠΈ Π΄ΠΈΠ°ΡΠ΅ΠΈ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠΉ ΡΠΊΠΎΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΠΉ ΠΏΡΠΎΠ±ΠΈΠΎΡΠΈΠΊ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΉ Π±ΠΈΡΠΈΠ΄ΠΎΠ±Π°ΠΊΡΠ΅ΡΠΈΠΈ ΠΈ ΡΠ½ΡΠ΅ΡΠΎΠΊΠΎΠΊΠΊΠΈ, ΠΈΠ»ΠΈ Π»Π°ΠΊΡΠΎΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ.
Some mechanisms of inflammation development in type 2 diabetes mellitus
Inflammation plays a key role in the development and progression of type 2 diabetes (T2DM), a disease characterized by peripheral insulin resistance and systemic glucolipotoxicity. The main source of inflammation in the early stages of the disease is visceral adipose tissue (VT). Macrophages are innate immune cells that are present in all peripheral tissues, including VT. Violation of the response of VT (MT) macrophages to changes in the microenvironment underlies aberrant inflammation and the development of local and systemic insulin resistance. The inflammatory activation of macrophages is regulated at several levels: stimulation of cell surface receptors, intracellular signaling, transcription, and metabolic levels. Which are activated by the transformation of macrophages along the pro-inflammatory or anti-inflammatory pathways. Such polarization of macrophages in modern immunology is divided into classical anti-inflammatory M1 polarization and alternative anti-inflammatory M2 polarization of macrophages. The M1 / M2 ratio of macrophages in the process of inflammation ensures the resolution of inflammation at different stages of its development. The review considers the main mechanisms involved in VT inflammation and the development of insulin resistance in T2DM, supported with the participation of immunocompetent cells, M1 / M2, as well as growth factors and humoral immunity factors secreted during this process
Prevalence and Severity of Breast Arterial Calcification on Routine Mammography
Aim. To determine the frequency of detection and severity of breast arterial calcification (BAC) among women undergoing mammography on the basis of medical institutions in Moscow.Material and methods. The analysis included 4274 digital mammograms of women aged 40-93 who underwent preventive or diagnostic mammography. Standard full-format digital mammograms were performed in craniocaudal and mediolateral oblique projections. In addition to the standard diagnosis of breast disease, all mammograms were evaluated for the presence of BAC. The severity of BAC was assessed on a 12-point scale: mild 3-4 points, moderate 5-6 points, severe 7-12 points.Results. The average frequency of BAC was 10.1%, in the middle age group 50-59 years β 6.0%. The incidence of BAC increased with age, from 0.4% to 0.6% in women <50 years of age to >50% in women β₯80 years of age. A statistically significant and pronounced correlation was found between the woman's age and the presence of BAC r Pearson =0.769 (p<0.001). There was also a less noticeable but statistically significant correlation between age and severity of BAC r Spearman =0.319 (p<0.001). Regression analysis made it possible to estimate the probability of CAD depending on age. In women <50 years of age, only mild to moderate calcification occurred, while those β₯65 years of age had a significant increase in the incidence of severe CAD.Conclusion. There was an expected increase with age in both prevalence and severity of BAC. Cases of severe BAC in women younger than 65 years of age and any BAC in women younger than 50 years of age are atypical and require clarification of their association with cardiovascular and other diseases
Π ΠΎΠ»Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½ΠΎΠ² Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡ-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π±ΡΠΎΠ½Ρ ΠΈΠΎΠ»ΠΈΡΠ°
The aim of research: To investigate the genetic polymorphism of immune response molecules (TNFΞ±-308G> A (rs1800629), IL4-589C>T (rs2243250), IL10-592C> A (rs1800872), IL10-819C> T (rs1800871), IL10-1082G>A (rs1800896), IL-17A-197G> A (rs2275913), IL- 17F-161His> Arg (rs763780), TLR-2-753Arg>Gln (rs5743708), TLR-6-249Ser>Pro (rs5743810) and assess their prognostic value in the development of acute virus-induced bronchiolitis.Materials and methods. The study included children of the first year of life, whose average age was 4.2 Β± 3.7 months. The main group consisted of 106 patients with moderate and severe acute viral bronchiolitis, more often associated with respiratory syncytial virus (56.6%). The control group consisted of 100 healthy children of the same age who had no signs of acute respiratory infection at the time of examination and did not receive passive immunoprophylaxis of respiratory syncytial infection. Genotyping was performed using the polymerase chain reaction method. The analysis of the results included the compliance with the Hardy-Weinberg law, the Ο 2 test, the relative chance, and its 95% confidence interval. To assess the distribution of the claimed gene polymorphisms and their alleles, we used the general (Ο2 test, df =2) and multiplicative (Ο2 test, df =1) inheritance models.Results. It was revealed that the risk of developing acute viral bronchiolitis is increased compared to the healthy population in carriers of the following genotypes: CC, ST gene IL10-819C> T (rs1800871), GG, AA gene IL-17A-197G> A (rs2275913), HisHis gene IL-17F-161His> Arg (rs763780), SerSer, SerPro gene TLR-6-249Ser> Pro (rs5743810), GG gene TNF-Ξ±-308G>A (rs1800629). The TT genotype of the IL10-819C>T (rs1800871) gene is associated with a high risk of developing bacterial complications (pneumonia) in viral bronchiolitis. Carriers of genotypes AA, CC of the IL10-592C> A (rs1800872) gene have an increased likelihood of a severe course of viral bronchiolitis.Conclusion. Genetic analysis of gene polymorphism IL10-592C> A (rs1800872), IL10-819C> T (rs1800871), IL-17A-197G> A (rs2275913), IL-17F-161His> Arg (rs763780), TLR-6-249Ser> Pro (rs5743810), TNF-Ξ±-308 G>A (rs1800629) can be used as a personalized developmental criterion acute virus-induced bronchiolitis in children, determining the severity of its course and the likelihood of complications.Π¦Π΅Π»Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° (TNFΞ±-308G>A (rs1800629), IL4-589C>T (rs2243250), IL10-592C>A (rs1800872), IL10-819C>T (rs1800871), IL10-1082G>A (rs1800896), IL-17A-197G>A (rs2275913), IL-17F-161His>Arg (rs763780), TLR2-753 Arg>Gln (rs5743708), TLR-6-249 Ser>Pro (rs5743810) ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈΡ
ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡ-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ Π΄Π΅ΡΠΈ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π° ΠΆΠΈΠ·Π½ΠΈ, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΊΠΎΡΠΎΡΡΡ
ΡΠΎΡΡΠ°Π²ΠΈΠ» 4,2Β±3,7 ΠΌΠ΅ΡΡΡΠ°. ΠΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ° β 106 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΡΡΠΌ Π²ΠΈΡΡΡΠ½ΡΠΌ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠΎΠΌ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ, ΡΠ°ΡΠ΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Ρ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎ-ΡΠΈΠ½ΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΠΌ Π²ΠΈΡΡΡΠΎΠΌ (56,6%). ΠΡΡΠΏΠΏΠ° ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ β 100 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄Π΅ΡΠ΅ΠΉ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°, Π½Π΅ ΠΈΠΌΠ΅Π²ΡΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΎΡΡΡΠΎΠΉ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π½Π΅ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΏΠ°ΡΡΠΈΠ²Π½ΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΡ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎ-ΡΠΈΠ½ΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΠ½Π°Π»ΠΈΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΊΠ»ΡΡΠ°Π» ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠ΅ Π·Π°ΠΊΠΎΠ½Ρ Π₯Π°ΡΠ΄ΠΈ β ΠΠ°ΠΉΠ½Π±Π΅ΡΠ³Π°, Ο2-ΡΠ΅ΡΡ, ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠ°Π½Ρ ΠΈ Π΅Π³ΠΎ 95% Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π». ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π·Π°ΡΠ²Π»Π΅Π½Π½ΡΡ
ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠ² Π³Π΅Π½ΠΎΠ² ΠΈ ΠΈΡ
Π°Π»Π»Π΅Π»Π΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΎΠ±ΡΡΡ (Ο2-ΡΠ΅ΡΡ, df=2) ΠΈ ΠΌΡΠ»ΡΡΠΈΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ (Ο2-ΡΠ΅ΡΡ, df=1) ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½Π°ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠ° ΠΏΠΎΠ²ΡΡΠ΅Π½ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠ΅ΠΉ Ρ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ²: Π‘Π‘, Π‘Π’ Π³Π΅Π½Π° IL10-819C>T (rs1800871), GG, ΠΠ Π³Π΅Π½Π° IL-17A-197G>A (rs2275913), HisHis Π³Π΅Π½Π° IL-17F-161His>Arg (rs763780), SerSer, SerPro Π³Π΅Π½Π° TLR-6-249Ser>Pro (rs5743810), GG Π³Π΅Π½Π° TNF-Ξ±-308G>A (rs1800629). ΠΠ΅Π½ΠΎΡΠΈΠΏ Π’Π’ Π³Π΅Π½Π° IL10-819C>T (rs1800871) Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ) ΠΏΡΠΈ Π²ΠΈΡΡΡΠ½ΠΎΠΌ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠ΅. ΠΠΎΡΠΈΡΠ΅Π»ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΠ, Π‘Π‘ Π³Π΅Π½Π° IL10-592C>A (rs1800872) ΠΈΠΌΠ΅ΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠ°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½ΠΎΠ² IL10-592C>A (rs1800872), IL10-819C>T (rs1800871), IL-17A-197G>A (rs2275913), IL-17F-161His>Arg (rs763780), TLR-6-249Ser>Pro (rs5743810), TNF-Ξ±-308G>A (rs1800629) ΠΌΠΎΠΆΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡ-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π±ΡΠΎΠ½Ρ
ΠΈΠΎΠ»ΠΈΡΠ° Ρ Π΄Π΅ΡΠ΅ΠΉ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΠΆΠ΅ΡΡΠΈ Π΅Π³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ
ΠΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π±Π»ΠΎΠΊΠ°Π΄Ρ Π½Π°Π΄ΠΊΠ»ΡΡΠΈΡΠ½ΠΎΠ³ΠΎ ΠΈ Π³ΡΡΠ΄Π½ΡΡ Π½Π΅ΡΠ²ΠΎΠ² ΠΏΡΠΈ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Ultrasound-guided regional anesthesia can be an effective way to achieve analgesia during implantation of permanent intravenous port systems.The aim of the study was to improve the quality of perioperative analgesia during placement of permanent intravenous port systems.Material and methods. The prospective randomized study included 93 patients with malignant neoplasms. Patients were randomized into 3 groups, 31 people each, who were implanted with a permanent intravenous port system in 2019β2022. Group 1 patients were implanted under local infiltration anesthesia (LIA). Ultrasound-guided pectoral nerves block (PECS1) in group 2 was supplemented by LIA. In group 3 ultrasoundguided selective supraclavicular (SC) nerve block was supplemented with LIA. Pain intensity was assessed on a 100 mm visual analog scale (VAS) at rest and while moving at 8, 16, 32 and 72 hours after implantation. The inflammatory postoperative stress response was assessed by the dynamics of C-reactive protein (CRP), interleukin 1-Ξ² (IL 1-Ξ²), interleukin-6 (IL-6). We also analyzed the correlation of proinflammatory cytokines levels with VAS-measured pain intensity at the stages of the study taking into account a potential relationship between IL-6 and IL-1Ξ² fluctuations and the severity of inflammatory and neuropathic pain.Results. In groups 2 (PECS1) and 3 (SC nerve block), pain intensity measured by VAS at rest and while conducting daily activities was significantly lower than in group 1 (LIA). CRP levels were also significantly lower in group 2 and 3 patients as compared to group 1. The lowest IL-6 and IL-1Ξ² concentrations after port implantation were revealed in a group 3 in 24 hours after the procedure, persisting through day 3. There was a correlationbetween proinflammatory cytokines levels and pain intensity.Conclusion. Implantation of an intravenous port system under local infiltration anesthesia causes a significant inflammatory response in cancer patients, which can be balanced by regional techniques. Selective supraclavicular nerve block in combination with a local anesthesia for intravenous port implantation demonstrated the greatest analgesic potential and requires significantly reduced amounts of local anesthetic compared to pectoral nerves block in combination with LIA, or only local infiltration anesthesia.ΠΠ΅ΡΠΎΠ΄Ρ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠΈ ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠ° ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ Π°Π½Π°Π»ΡΠ³Π΅Π·ΠΈΠΈ ΠΏΡΠΈ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΡ
Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΡ
ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π£Π»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π°Π½Π°Π»ΡΠ³Π΅Π·ΠΈΠΈ ΠΏΡΠΈ ΡΡΡΠ°Π½ΠΎΠ²ΠΊΠ΅ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΡ
Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΡ
ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠΈΠ»ΠΈ 93 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ, ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° 3 Π³ΡΡΠΏΠΏΡ ΠΏΠΎ 31 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΡ Π² ΠΊΠ°ΠΆΠ΄ΠΎΠΉ, ΠΊΠΎΡΠΎΡΡΠΌ Π² 2019β2022 Π³Π³. ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΡ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΡ ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ 1-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΠΏΠΎΠ΄ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠ΅ΠΉ (ΠΠΠ). ΠΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ 2-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π±Π»ΠΎΠΊΠ°Π΄Ρ Π³ΡΡΠ΄Π½ΡΡ
Π½Π΅ΡΠ²ΠΎΠ² (ΠΠΠ)+ΠΠΠ ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠ°, Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΡΡ ΠΠΠ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 3-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΡ Π±Π»ΠΎΠΊΠ°Π΄Ρ Π½Π°Π΄ΠΊΠ»ΡΡΠΈΡΠ½ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° (Π‘ΠΠΠ) ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠ°, Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΡΡ ΠΠΠ. ΠΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ Π±ΠΎΠ»ΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΠΎΠΉ Π°Π½Π°Π»ΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π»Π΅ (ΠΠΠ¨) Π² ΠΏΠΎΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΈ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΠΈ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡ 100 ΠΌΠΌ Π»ΠΈΠ½Π΅ΠΉΠΊΡ, ΡΠ΅ΡΠ΅Π· 8, 16, 32 ΠΈ 72 Ρ ΠΎΡ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ. ΠΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΡΡΡΠ΅ΡΡ-ΠΎΡΠ²Π΅Ρ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ Π‘-ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° (Π‘Π Π), ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π° 1-Ξ² (IL 1-Ξ²), ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-6 (IL-6). Π£ΡΠΈΡΡΠ²Π°Ρ ΡΠ²ΡΠ·Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ IL-6 ΠΈ IL-1Ξ² Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΈ Π½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π±ΠΎΠ»ΠΈ, ΠΏΡΠΎΠ²Π΅Π»ΠΈ Π°Π½Π°Π»ΠΈΠ· ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π±ΠΎΠ»ΠΈ ΠΏΠΎ ΠΠΠ¨ Π½Π° ΡΡΠ°ΠΏΠ°Ρ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π³ΡΡΠΏΠΏΠ°Ρ
2 (ΠΠΠ) ΠΈ 3 (Π‘ΠΠΠ) Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ Π±ΠΎΠ»ΠΈ ΠΏΠΎ ΠΠΠ¨ Π² ΠΏΠΎΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΈ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΠΈ Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΌΠ΅Π½ΡΡΠ΅, ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ 1 (ΠΠΠ). ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π‘Π Π Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 2-ΠΉ ΠΈ 3-ΠΉ Π³ΡΡΠΏΠΏ, Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ Π³ΡΡΠΏΠΏΡ, Π±ΡΠ»Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π½ΠΈΠΆΠ΅. ΠΡΠΌΠ΅ΡΠΈΠ»ΠΈ, ΡΡΠΎ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ IL-6 ΠΈ IL-1Ξ² ΠΏΠΎΡΠ»Π΅ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠΎΡΡ β ΡΠΈΡΡΠ΅ΠΌΡ Π±ΡΠ»Π° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΠ΅ΡΠ΅Π· ΡΡΡΠΊΠΈ Π² 3-ΠΉ Π³ΡΡΠΏΠΏΠ΅, ΠΏΡΠΈΡΠ΅ΠΌ ΠΎΡΠ»ΠΈΡΠΈΡ ΠΏΠΎ IL-6 Π² ΡΠΎΠΉ ΠΆΠ΅ Π³ΡΡΠΏΠΏΠ΅ ΡΠΎΡ
ΡΠ°Π½ΡΠ»ΠΈΡΡ ΠΈ Π½Π° 3-ΠΈ ΡΡΡ. ΠΡΡΠ²ΠΈΠ»ΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΡ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡΡ Π±ΠΎΠ»ΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ, Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π½Π°Ρ ΠΏΠΎΠ΄ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠ΅ΠΉ, Π²ΡΠ·ΡΠ²Π°Π΅Ρ Π·Π½Π°ΡΠΈΠΌΡΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΎΡΠ²Π΅Ρ Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π½ΠΈΠ²Π΅Π»ΠΈΡΠΎΠ²Π°Π½ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ². Π‘Π΅Π»Π΅ΠΊΡΠΈΠ²Π½Π°Ρ Π±Π»ΠΎΠΊΠ°Π΄Π° Π½Π°Π΄ΠΊΠ»ΡΡΠΈΡΠ½ΠΎΠ³ΠΎ Π½Π΅ΡΠ²Π° Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠ΅ΠΉ ΠΏΡΠΈ ΠΈΠΌΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΡ
ΠΏΠΎΡΡ-ΡΠΈΡΡΠ΅ΠΌ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΌ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΠΎΠΌ ΠΈ ΡΡΠ΅Π±ΡΠ΅Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΌΠ΅Π½ΡΡΠ΅Π³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ Π°Π½Π΅ΡΡΠ΅ΡΠΈΠΊΠ°, Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π±Π»ΠΎΠΊΠ°Π΄ΠΎΠΉ Π³ΡΡΠ΄Π½ΡΡ
Π½Π΅ΡΠ²ΠΎΠ² Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΠΌΠ΅ΡΡΠ½ΡΡ
Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ β ΡΠΎΠ»ΡΠΊΠΎ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠ΅ΠΉ
Assessment of the Severity of Breast Artery Calcification on a Mammogram: Intraoperator and Interoperator Reproducibility
Purpose. To study approaches to the quantitative assessment of breast arterial calcification (BAC) β a new surrogate marker of high cardiovascular risk in women, to determine the most detailed way to quantify BAC and to assess the reproducibility of these parameters.Material and methods. Mammograms of 1,078 women were analyzed for the presence of BAC. The intraoperator reproducibility of the assessment of the severity of BAC using a 12-point scale (Margolies L et al., 2016) was studied by analyzing 20 mammograms by the same operator twice with an interval of at least 2 weeks. Inter-operator reproducibility was studied by analyzing 99 mammograms by two independent operators.Results. When assessing the intraoperative reproducibility of the total score for each mammary gland, the exact coincidence of the results was noted in 70% (95% confidence interval [CI] 53.5-83.4), in cases of difference of no more than 1 point β in 27.5% (95%CI 14.6-43.9), only in 1 case the difference in assessments was 2 points. No systematic error was found between the two measurements (p=1.0), the correlation coefficient was rs=0.973. The assessment of inter-operator reproducibility showed that the exact coincidence of indicators was present in 48.5% (95%CI 41.3-55.7), in 91.4% (95% CI 86.6-94.9) cases, the total score for each the mammary gland differed by no more than 1 point. There was no systematic error between the measurements of the two experts (p=0.438), the correlation coefficient was rs=0.942.Conclusion. A good intraoperator and interoperator reproducibility of indicators of the severity of BAC on a 12-point scale has been shown, which makes it possible to recommend it for use in science and practice
- β¦